DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas

British Journal of Cancer

Volumn 108, Issue 8, 2013, Pages 1732-1742

  Kamieniak, M M ^a   Munoz Repeto I ^a   Rico, D ^a   Osorio, A ^a,b   Urioste, M ^a,b   Garcia Donas J ^a,c   Hernando, S ^d   Robles Diaz L ^e   Ramon Y Cajal T ^f   Cazorla, A ^g   Saez R ^h   Garcia Bueno J M ⁱ   Domingo, S ^a   Borrego, S ^j   Palacios, J ^k   Van De Wiel, M A ^l   Ylstra, B ^l   Benitez J ^a,b   Garcia M J ^a,b  

^a Structural Biology and Biocomputing Programme   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c Centro Integral Oncologico Clara Campal   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL SANT PAU   (Spain)

^g Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; EPITHELIAL OVARIAN CARCINOMA; FAMILIAL CANCER; FEMALE; GENE DOSAGE; GENE LOSS; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; FEMALE; FORMALDEHYDE; GENES, BRCA1; GENES, BRCA2; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; TISSUE FIXATION;

EID: 84877030741     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.141     Document Type: Article

References (46)

1. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 30: 2654-2663.
2. Bast Jr RC, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
3. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040.
4. Berns EM, Bowtell DD (2012) The changing view of high-grade serous ovarian cancer. Cancer Res 72: 2701-2704.
5. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benitez J, Garcia MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lazaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg A, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307: 382-390.
6. Bowtell DD (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808.
7. Buffart TE, Israeli D, Tijssen M, Vosse SJ, Mrsic A, Meijer GA, Ylstra B (2008) Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer 47: 994-1004.
8. Didraga MA, van Beers EH, Joosse SA, Brandwijk KI, Oldenburg RA, Wessels LF, Hogervorst FB, Ligtenberg MJ, Hoogerbrugge N, Verhoef S, Devilee P, Nederlof PM (2011) A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res Treat 130: 425-436.
9. Domanska K, Malander S, Staaf J, Karlsson A, Borg A, Jonsson G, Nilbert M (2010) Genetic profiles distinguish different types of hereditary ovarian cancer. Oncol Rep 24: 885-895.
10. Dong Q, Meng P, Wang T, Qin W, Wang F, Yuan J, Chen Z, Yang A, Wang H (2010) MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS ONE 5: e10147.
11. Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
12. Focken T, Steinemann D, Skawran B, Hofmann W, Ahrens P, Arnold N, Kroll P, Kreipe H, Schlegelberger B, Gadzicki D (2011) Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors. Cytogenet Genome Res 135: 84-92.
13. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, Santos J, Le N, Moravan V, Swenerton K (2008) Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 39: 1239-1251.
14. Gronwald J, Jauch A, Cybulski C, Schoell B, Bohm-Steuer B, Lener M, Grabowska E, Gorski B, Jakubowska A, Domagala W, Chosia M, Scott RJ, Lubinski J (2005) Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. Int J Cancer 114: 230-236.
15. Hedenfalk I, Ringner M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson H, Meltzer P, Borg A, Trent J (2003) Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 100: 2532-2537.
16. Israeli O, Gotlieb WH, Friedman E, Goldman B, Ben-Baruch G, Aviram-Goldring A, Rienstein S (2003) Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH. Gynecol Oncol 90: 629-636.
17. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB (2012) Genome sequencing identifies a basis for everolimus sensitivity. Science 338: 221.
18. Jonsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, Stratton M, Ringner M, Borg A, Weber BL (2005) Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res 65: 7612-7621.
19. Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM (2009) Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 116: 479-489.
20. Kalloger SE, Kobel M, Leung S, Mehl E, Gao D, Marcon KM, Chow C, Clarke BA, Huntsman DG, Gilks CB (2011) Calculator for ovarian carcinoma subtype prediction. Mod Pathol 24: 512-521.
21. Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, Ewanowich CA, Soslow RA, Gilks CB (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 33: 14-21.
22. Koul A, Malander S, Loman N, Pejovic T, Heim S, Willen R, Johannsson O, Olsson H, Ridderheim M, Borg AA (2000) BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. Int J Gynecol Cancer 10: 289-295.
23. Kurman RJ, Shih IEM (2011) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34: 433-443.
24. Leunen K, Gevaert O, Daemen A, Vanspauwen V, Michils G, De Moor B, Moerman P, Vergote I, Legius E (2009) Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways. Hum Mutat 30: 1693-1702.
25. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28: 496-504.
26. Mangia A, Chiarappa P, Tommasi S, Chiriatti A, Petroni S, Schittulli F, Paradiso A (2008) Genetic heterogeneity by comparative genomic hybridization in BRCAx breast cancers. Cancer Genet Cytogenet 182: 75-83.
27. Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benitez J (2008) Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 27: 3165-3175.
28. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T, Blanco A, Grana B, Duran M, Velasco E, Chirivella I, Cardenosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martinez E, Guillen C, Salazar R, San Roman C, Antoniou AC, Urioste M, Benitez J (2008) The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 14: 2861-2869.
29. Patael-Karasik Y, Daniely M, Gotlieb WH, Ben-Baruch G, Schiby J, Barakai G, Goldman B, Aviram A, Friedman E (2000) Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. Cancer Genet Cytogenet 121: 26-32.
30. Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 124: 347-353.
31. Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi SC, Yu Q (2011) FOXQ1 regulates epithelial-mesenchymal transition in human cancers. Cancer Res 71: 3076-3086.
32. Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther SA (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28: 1207-1215.
33. Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, Ayhan A, Wells D, Fishman A, Gore M, DiCioccio RA, Piver MS, Whittemore AS, Ponder BA, Gayther SA (2003) BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 63: 417-423.
34. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
35. Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19: 7-15.
36. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, Kauff ND, Levine DA (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25: 625-636.
37. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 11: R47.
38. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
39. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK (2008) Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 118: 1750-1764.
40. van de Wiel DF, Zhang WL (2007) Identification of pork quality parameters by proteomics. Meat Sci 77: 46-54.
41. Van Wieringen WN, Van De Wiel MA, Ylstra B (2008) Weighted clustering of called array CGH data. Biostatistics 9: 484-500.
42. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FB, Couch F, Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G (2010) Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 123: 661-677.
43. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, Karlan BY (2008) Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res 14: 7645-7651.
44. Wang ZC, Birkbak NJ, Culhane A, Drapkin RI, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, Defazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA (2012) Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18: 5806-5815.
45. World Health Organization (2004) Histological Typing of Ovarian Tumours. Springer: Berlin.
46. Zweemer RP, Ryan A, Snijders AM, Hermsen MA, Meijer GA, Beller U, Menko FH, Jacobs IJ, Baak JP, Verheijen RH, Kenemans P, van Diest PJ (2001) Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 81: 1363-1370.